Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | LCK | P06239 | 3/20 | 0.43 |
| ▸ | MST1R | Q04912 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | HGF | P14210 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 8/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.40 |
| ▸ | CSF1R | P07333 | 4/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076008 | 0.93 | MET (0.44) | METKDRLCKMST1RAURKA | |
| SCHEMBL3560801 | 0.92 | MET (0.49) | METKDRLCKMST1RAURKA | |
| SCHEMBL3558835 | 0.92 | MET (0.43) | METKDRLCKMST1RAURKA | |
| SCHEMBL3565458 | 0.92 | MET (0.42) | METKDRLCKMST1RAURKA | |
| SCHEMBL16083953 | 0.89 | MET (0.44) | METKDRLCKMST1RAURKA | |
| SCHEMBL3562727 | 0.88 | MET (0.42) | METKDRLCKMST1RAURKA | |
| SCHEMBL3562448 | 0.87 | BRAF (0.43) | METKDRLCKMST1RAURKA | |
| SCHEMBL3564327 | 0.86 | MET (0.47) | METKDRLCKMST1RAURKA | |
| SCHEMBL16076007 | 0.85 | MET (0.44) | METKDRLCKMST1RAURKA | |
| SCHEMBL16076010 | 0.85 | MET (0.51) | METKDRLCKMST1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968286-B1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2125781-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214544-A1 | Substituted heterocycles and methods of use | HGF, MET, HGFAC | MET 2/4885KDR 65/4885LCK 860/4885 |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | MET 194/4885KDR 72/4885LCK 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.